CBU
TVTX icon

CIBC Bancorp USA’s Travere Therapeutics TVTX Stock Holding History

CIBC Bancorp USA’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$429K Buy
+7,551
New +$335K ﹤0.01% 1365
2025
Q3 		$225K Buy
+9,398
New +$177K ﹤0.01% 1215

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CIBC Bancorp USA's TVTX Position: Q2 2026 in Review

CIBC Bancorp USA opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 7,551 shares worth $429K. The stake represents ﹤0.01% of the portfolio and ranks #1365 among its holdings. This is a return to the name: CIBC Bancorp USA previously reported a position in TVTX as recently as Q3 2025.

CIBC Bancorp USA first reported a position in TVTX in Q3 2025 and has held it in 2 quarters since. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • CIBC Bancorp USA held 7,551 shares of Travere Therapeutics worth $429K as of Q2 2026.
  • Travere Therapeutics was a new CIBC Bancorp USA position in Q2 2026.
  • Travere Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #1365 holding.
  • CIBC Bancorp USA first reported a position in Travere Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.